Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Carrington Laboratories (CARN) -- Ignore unavailable to you. Want to Upgrade?

To: BlueCheap who wrote (189)	4/2/1998 3:46:00 PM
From: Michael Theye	Respond to of 197

Carrington Laboratories Continues International Expansion With Two New Contracts PR Newswire, Wednesday, April 01, 1998 at 08:48 IRVING, Texas, April 1 /PRNewswire/ -- Carrington Laboratories, Inc., (NASDAQ:CARN) has announced the signing of two new international contracts, bringing to 21 the number of international contracts the company has executed since a priority was placed on international sales. Carrington executed a contract and has received an initial order for The Carrington(R) Patch from Schein-Rexodent, Ltd., a United Kingdom-based company, and wholly-owned subsidiary of Henry Schein, based in the U.S. Under the contract, The Patch will be sold in the UK and Ireland under Schein's own trademark. Formal launch of the product is expected this summer. Carrington has also signed an agreement with Hemopharm, GmbH, a Frankfurt (Germany) company that will distribute Carrington's oral and wound care products in Yugoslavia through its sister company Hemofarm. Hemofarm is the second largest pharmaceutical distribution company in Yugoslavia. It currently has six Carrington products under registration with six more to follow soon. The first set of products is expected to receive approval this summer with initial launch shortly thereafter. "International revenues for wound care and oral technologies are growing according to plan," said Chris Record, vice president of Business Development. "Now that we have our ISO 9001 designation and 'CE' mark, we anticipate international activities will continue to grow throughout the year. Carrington, as an ISO 9001 company, now has international recognition as a quality provider. Based on this recognition, we expect continued international growth." Carrington Laboratories, Inc., is an emerging research-based pharmaceutical and medical device company engaged in developing naturally- occurring, complex carbohydrates, other nature-based therapeutics and oral technology products, and in manufacturing and marketing products for the management of wounds and for consumer products made from naturally-occurring Aloe vera L. Carrington currently markets more than 70 application-specific products.